ArticleAnnals of hematology2025
Nomogram for predicting the overall survival and disease-specific survival of adult patients with primary diffuse large B-cell lymphoma, leg type based on the SEER database.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diffuse Large B-Cell Lymphoma Presenting as a Thigh Mass: A Case Report.The Permanente journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Primary diffuse large B-cell lymphoma, leg type (PCDLBCL, LT) is a rare lymphoma with a poor prognosis. An accurate predictive model for the prognosis of these patients is lacking. Here, we retrospectively analyzed the clinical data of 968 adult patients who were diagnosed with PCDLBCL, LT between 2000 and 2020 obtained from the Surveillance, Epidemiology and End Results (SEER) database. Multivariate Cox regression analysis revealed that age, marital status and radiation were independent prognostic factors for overall survival (OS), while age, Ann Arbor stage and radiation were independent prognostic factors for disease-specific survival (DSS). Nomograms were constructed to predict 1-, 3- and 5-year OS and DSS. The concordance indices, receiver operating characteristic curves and calibration curves revealed that the established nomograms had good accuracy in predicting the outcomes of patients with PCDLBCL, LT. The web-based calculators were subsequently developed to provide individualized predictions for OS and DSS in patients with PCDLBCL, LT. Moreover, according to the risk scores of the nomograms, patients were divided into low-, median-, and high-risk groups. In conclusion, the nomograms and accompanying web-based survival calculators offer practical tools for individualized prediction of OS and DSS in patients with PCDLBCL, LT. Risk stratification based on these tools may assist clinicians in identifying high-risk patients and guiding optimal treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.